Washington State Pharmacy and Therapeutics Committee Drug Utilization Review Board Date: April 19, 2017

Time: 9 a.m. to 2:15 p.m.

Port of Seattle "International A" Conference Room Seattle-Tacoma International Airport 17801 International Blvd., Seattle, WA 98158

	17601 International bivu., Seattle, vi	A 90100
9 a.m.	Welcome & Introductions	Michael Johnson, Committee Chair
	Pharmacy & Therapeutics Committee Convenes	
9:05 a.m.	P&T / DUR process overview & questions	All
9:30 a.m.	Antidepressants* update	Gerald Gartlehner, MD, MPH, OHSU
10:10 a.m.	Statins* expanded scan	Rebecca Holmes, MD, MS, OHSU
10:30 a.m.	Break	All
10:45 a.m.	PCSK9 Inhibitors* expanded scan	Marian McDonagh, PharmD, OHSU
11:05 a.m.	Hormone Replacement Therapy* scan	Brittany H. Lazur, MPH, OHSU
11:15 a.m.	Insomnia* scan	Brittany H. Lazur, MPH, OHSU
11:25 a.m.	Pharmacy & Therapeutics Committee Adjourns	Michael Johnson, Committee Chair
	Drug Utilization Review (DUR) Board Convenes	
11:25 a.m.	Antidepressants policy*	Ryan Pistoresi, HCA
11:40 a.m.	Drug class policy: Insomnia* PCSK9 Inhibitors* Hormone Replacement Therapy* Statins*	Ryan Pistoresi, HCA
12 p.m.	Lunch	All
1 p.m.	Drug Utilization Review (DUR) Board Convenes	Michael Johnson, Committee Chair
1 p.m.	NSAIDs policy*	Ryan Pistoresi, HCA
1:10 p.m.	Colchicine policy*	Ryan Pistoresi, HCA
1:20 p.m.	Cyclobenzaprine policy*	Ryan Pistoresi, HCA
1:30 p.m.	Deflazacort (Emflaza) policy*	Ryan Pistoresi, HCA
2:15 p.m.	Drug Utilization Review Board Adjourns	Michael Johnson, Committee Chair

^{*} Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby. Committee discussion and motions will follow stakeholder comments.